| Signature Homenow | |
| 759 Sw Federal Hwy Ste 300, Stuart, Florida 34994 | |
| (772) 287-5111 | |
| Name | Signature Homenow |
|---|---|
| Location | 759 Sw Federal Hwy Ste 300, Stuart, Florida |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 108274 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 33404, 33406, 33407, 33408, 33410, 33411, 33412, 33413, 33414, 33415, 33417, 33418, 33426, 33428, 33431, 33436, 33437, 33444, 33445, 33446, 33455, 33460, 33461, 33462, 33463, 33467, 33472, 33477, 33480, 33483, 33484, 33487, 34946, 34947, 34949, 34950, 34951, 34952, 34953, 34956, 34957, 34972, 34974, 34981, 34982, 34983, 34984, 34986, 34987, 34990, 34994, 34996, 34997 |
| NPI Number | 1679901185 |
| Organization Name | SHC HOME HEALTH SERVICES - JENSEN BEACH, LLC |
| Doing Business As | SIGNATURE HOMENOW |
| Address | 759 Sw Federal Hwy Ste 300, Royal Palm Financial Center Bldg 3, Stuart, FL 34994 |
| Phone Number | 772-287-5111 |
News Archive
Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).
Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."
Genetics can be used to predict a patient's response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online today in the American Journal of Psychiatry.
By mapping out more than 100,000 immune cells in patients with Crohn's disease, Mount Sinai researchers have discovered a signature of cells that are involved in a type of the disease that does not respond to treatment, according to a study published in Cell in August.
Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.
› Verified 7 days ago
| Quality Rating: |
News Archive
Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).
Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."
Genetics can be used to predict a patient's response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online today in the American Journal of Psychiatry.
By mapping out more than 100,000 immune cells in patients with Crohn's disease, Mount Sinai researchers have discovered a signature of cells that are involved in a type of the disease that does not respond to treatment, according to a study published in Cell in August.
Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 94.7 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.8 | 99.6 |
| How often the home health team checked patients for depression | 94.2 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 66.2 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 61.6 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 87.9 | 96.4 |
News Archive
Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).
Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."
Genetics can be used to predict a patient's response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online today in the American Journal of Psychiatry.
By mapping out more than 100,000 immune cells in patients with Crohn's disease, Mount Sinai researchers have discovered a signature of cells that are involved in a type of the disease that does not respond to treatment, according to a study published in Cell in August.
Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 85.1 | 79.6 |
| How often patients got better at getting in and out of bed | 87 | 81.1 |
| How often patients got better at bathing | 86.4 | 82.3 |
| How often patients’ breathing improved | 89.7 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 96.4 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 78.2 | 75 |
| How often home health patients had to be admitted to the hospital | 15.8 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 11.8 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 95.5 | 94 |
News Archive
Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).
Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."
Genetics can be used to predict a patient's response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online today in the American Journal of Psychiatry.
By mapping out more than 100,000 immune cells in patients with Crohn's disease, Mount Sinai researchers have discovered a signature of cells that are involved in a type of the disease that does not respond to treatment, according to a study published in Cell in August.
Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.
› Verified 7 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).
Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."
Genetics can be used to predict a patient's response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online today in the American Journal of Psychiatry.
By mapping out more than 100,000 immune cells in patients with Crohn's disease, Mount Sinai researchers have discovered a signature of cells that are involved in a type of the disease that does not respond to treatment, according to a study published in Cell in August.
Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.
› Verified 7 days ago
The patient survey data of Signature Homenow is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 86 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 85 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 78 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 83 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 73 | 78 |
News Archive
Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).
Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."
Genetics can be used to predict a patient's response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research. The findings were published online today in the American Journal of Psychiatry.
By mapping out more than 100,000 immune cells in patients with Crohn's disease, Mount Sinai researchers have discovered a signature of cells that are involved in a type of the disease that does not respond to treatment, according to a study published in Cell in August.
Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.
› Verified 7 days ago
Visiting Nurse Association Of Florida Inc Location: 2400 Se Monterey Rd Ste 300, Stuart, Florida 34996 Ratings: Phone: (772) 286-1844 | |
Anchor Home Health Services, Llc Location: 3725 Se Ocean Blvd Ste 205, Stuart, Florida 34996 Ratings: Phone: (772) 463-6016 | |
Signature Homenow Location: 759 Sw Federal Hwy Ste 300, Stuart, Florida 34994 Ratings: Phone: (772) 287-5111 | |
Superior Care Home Health Agency Llc Location: 1111 Se Federal Hwy Ste 227, Stuart, Florida 34994 Ratings: NA Phone: (772) 678-6994 |